Characteristics of 172 Patients | ||
---|---|---|
 | No | % |
Age (years) | Â | Â |
Median (range) | 73 (54–92) | |
Sex | Â | Â |
Male | 100 | 58 |
Female | 72 | 42 |
T stage | Â | Â |
IA (T1a-c) | 110 | 64 |
IB (T2a) | 39 | 23 |
IIA (T2b) | 23 | 13 |
Pathologic confirmation | Â | Â |
Yes ( spino/adeno) | 82 (44/70) | 48 |
No | 90 | 52 |
PET | Â | Â |
Yes | 105 | 61 |
No | 67 | 39 |
COPD (GOLD) | Â | Â |
0 | 43 | 25 |
1 | 23 | 13 |
2 | 42 | 24 |
3 | 37 | 22 |
4 | 27 | 16 |
FEV1% predicted | Â | Â |
Median (range) | 55% (20–137) |  |
≥ 50% | 108 | 63 |
< 50% | 64 | 37 |
AACCI | Â | Â |
Median (range) | 5 points (2-10) | Â |
2–5 | 114 | 66 |
6–10 | 58 | 34 |
Performance Status | Â | Â |
0 | 45 | 26 |
1 | 88 | 51 |
2 | 39 | 23 |
Tumor location | Â | Â |
Central | 23 | 13 |
Peripheral | 149 | 87 |
Dose fractionation | Â | Â |
60–54 Gy/3fr. | 92 | 53 |
30–33 Gy/1fr. | 19 | 11 |
60–55 Gy/5fr. | 42 | 24 |
50Â Gy/5fr. | 19 | 11 |
BED10prescribed | Â | Â |
Median (range) | 151.2 (94–180) |  |
≥ 151.2 Gy | 82 | 48 |
< 151.2 Gy | 90 | 52 |
BED10maximum | Â | Â |
Median (range) | 251.6 (135–398) |  |
≥ 251.6 Gy | 75 | 44 |
< 251.6 Gy | 97 | 56 |